Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $70.78 on AbbVie Inc. (NYSE:ABBV) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $4.81 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of AbbVie Inc. (NYSE:ABBV) stands at 18.49.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For AbbVie Inc. Common Stock, the PEG ratio for coming 3-5 years is 0.82.
The technical analysis highlights that AbbVie Inc. Common Stock current is trading $-1.32 points away or -2.02% from its 50-day moving average of $65.44. Further it is trading $2.99 or +4.89% away its 200-day moving average of $61.13.
The 52-week high of AbbVie Inc. (NYSE:ABBV) was $68.12 while lowest point recorded in 52-week was $45.45. It implies if stock price makes a movement of over $-4.00, it will record a new 52-week high. In the case of +41.08% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...